Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies
<p>Design and characterisation of HIV-1 CAP255 Env. (<b>A</b>) Schematic diagram of the original wildtype HIV-1 CAP255 gp160, the truncated CAP255 gp150 and the soluble CAP255 gp140 SpyTag. HIV-1 SP—signal peptide; REKR—furin cleavage site; TM—transmembrane region; TPA SP-tissue plasminogen activator leader sequence; FL-flexible linker; G501C—glycine-to-cysteine mutation at amino acid 501; T605C—threonine-to-cysteine mutation at amino acid 605; I559P—isoleucine-to-proline mutation at amino acid 559. (<b>B</b>) Western blot confirming expression of CAP255 gp140 SpyTag in the media of stably transfected HEK293 cells at passage 5 (P5) and 10 (P10). MW—molecular weight marker. (<b>C</b>) Graph showing the SEC profile of CAP255 gp140 SpyTag and the fractions analysed in (<b>D</b>) are shown. (<b>D</b>) Coomassie-stained Blue Native PAGE of CAP255 gp140 SpyTag purified by lectin affinity chromatography (LAC) and subsequent SEC fractions 36 to 46. CAP255 gp140 SpyTag trimers (***), dimers (**), monomers (*) and molecular weight in kDa (MW) are indicated.</p> "> Figure 2
<p>Western blotting confirming the expression of CAP255 gp150 Env and mosaic Gag.</p> "> Figure 3
<p>SpyTag–SpyCatcher coupling efficiency. (<b>A</b>) Coomassie-stained SDS-PAGE analysis of coupling reaction with MBP SpyTag**** and SpyCatcher mi3***** NPs at 1:1 and 1:2 molar ratios. Doubling the concentration of MBP SpyTag increased the amount of unbound MBP SpyTag****, and only a negligible amount of unbound SpyCatcher mi3***** remained. (<b>B</b>) Western blot (anti-His tag) analysis of CAP255 gp140 SpyTag:SpyCatcher mi3* coupling reaction. Doubling the concentration of CAP255 gp140 SpyTag had no noticeable effect on the amount of CAP255 gp140 SpyTag SpyCatcher mi3*, as unbound SpyCatcher mi3***** was still clearly visible. (<b>C</b>) Western blot (anti-Env) showing a large excess of CAP255 gp140 SpyTag** and an increase in CAP255 gp140 SpyTag SpyCatcher mi3* after doubling the concentration of CAP255 gp140 SpyTag** in the coupling reaction. (<b>D</b>) Diagrammatic representation of the proteins detected.</p> "> Figure 4
<p>NS-EM of the SpyCatcher mi3 NPs coupling. (<b>A</b>) SpyCatcher mi3 NPs and 2D class average (inset) showing successful assembly. (<b>B</b>) MBP SpyTag–SpyCatcher mi3 NPs; MBP densities make the SpyCatcher mi3 wall appear slightly thicker. (<b>C</b>) CAP255-gp 140 SpyTag–SpyCatcher mi3 NPs; excess Env particles can be seen in the background. Clear additional density corresponding to externally protruding Env trimers can be seen on the surface of the NP in the raw images and 2D class average (inset). The slight blurring of Env trimers, visible in the 2D class average, is likely due to conformational flexibility. (<b>D</b>) Three-dimensional map of SpyCatcher mi3 NP docked with the atomic coordinates of mi3 (PDB ID: 7B3Y in light blue), demonstrating good particle assembly. Additional density was observed at the pentagonal NP faces. (<b>E</b>,<b>F</b>) In negative stain, the details of this additional density could not be resolved, but its dimensions and shape correspond closely to five copies of SpyCatcher protein (PDB ID: 4MLS in dark blue). (<b>G</b>) CAP255 gp140 SpyTag–SpyCatcher mi3 NP reconstruction; the mi3 NP (PDB ID: 7B3Y in light blue) maintains rigidity and is surrounded by twelve regularly spaced Env trimers with high occupancy (36 copies of CAP255 gp140 SpyTag). The atomic structures of the Env trimer (PDB ID: 5JSA in yellow) correspond closely to the contours of the 3D map and are aligned along the five-fold axis. The clear 5-fold symmetry of the trimers is an artefact of imposing icosahedral symmetry on the trimer at the icosahedral 5-fold axes. (<b>H</b>,<b>I</b>) An additional disk of density corresponding to (<b>D</b>) was observed at the base of each Env trimer.</p> "> Figure 5
<p>Cryo-EM analysis of the assembled nanoparticles. (<b>A</b>) Two-dimensional class average of the CAP255 gp140 SpyTag SpyCatcher mi3 NP visualised along the icosahedral 2-fold symmetry axis. The stable mi3 core is surrounded by flexible CAP255 gp140 densities. (<b>B</b>) Density view of the icosahedral 3D reconstruction, rotated to the same orientation as (<b>A</b>). (<b>C</b>) Surface representation of the reconstruction; Env densities are centred on the 5-fold icosahedral symmetry axes. (<b>D</b>) Masked and symmetry-imposed mi3 NP density (blue) at 5.3 Å resolution, and CAP255 gp140 SpyTag–SpyCatcher density (yellow) at 17.7 Å resolution after focused classification without imposing symmetry. The atomic coordinates of mi3 (PDB ID: 7B3Y in light blue), SpyCatcher/SpyTag (PDB ID: 4MLS in dark blue and SpyTag in red) and the gp140 trimer (PDB ID: 5JSA yellow) are shown docked into the 3D reconstructions. (<b>E</b>,<b>F</b>) Five SpyCatcher monomers associate symmetrically about the five-fold axis to form a disk. The points of attachment to mi3 can be seen. Three-fold symmetric CAP255 gp140 SpyTag binds to the SpyCatcher disk. (<b>G</b>–<b>I</b>) The association between CAP255 gp140 SpyTag and SpyCatcher mi3 visualised along the icosahedral 5-fold symmetry axis shows the symmetry mismatch between the CAP255 gp140 SpyTag trimer and SpyCatcher pentamer. This results in a ratio of 3:2 (covalently linked SpyCatcher mi3: unlinked SpyCatcher mi3).</p> "> Figure 6
<p>Binding and neutralising antibody responses in rabbits. (<b>A</b>) Vaccination schedule and bleeds. (<b>B</b>) Binding antibody titres to CAP255 gp140 in sera of vaccinated rabbits. Where no binding was observed, the endpoint titre was plotted as 10. (<b>C</b>) Neutralising antibody titres in rabbit sera were measured using the pseudovirus-based TZM-bl neutralisation assay. The serum was taken 2 weeks after the second DNA prime (week 6), 2 weeks after the nanoparticle inoculation (week 14) and 4 weeks after the nanoparticle inoculation (week 16). Neutralisation titres were negative for all time points in the MuLV negative-control neutralisation assay. The 50% neutralisation titres (ID50) are colour-coded to reflect their potency range. Titres below 40 were considered non-neutralising and were not colour-coded.</p> "> Figure 7
<p>Neutralising antibody responses in rabbits. (<b>A</b>) Vaccination schedule and bleeds. (<b>B</b>) Neutralising antibody titres in rabbit sera were measured using the TZM-bl assay. The serum was taken 2 weeks after the second DNA prime (2nd DNA) and 2 weeks after each nanoparticle inoculation (1st NP, 2nd NP and 3rd NP). Neutralisation titres were negative for all time points in the MuLV negative-control neutralisation assay. The 50% neutralisation titres are colour-coded to reflect their potency range. Titres below 20 were considered non-neutralising and were not colour-coded.</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Plasmids, Antibodies, Cell Lines, Media and Reagents
2.2. CAP255 gp140 SpyTag & gp150 Design
2.3. CAP255 gp150 Expression and Characterisation
2.4. CAP255 gp140 SpyTag Expression, Isolation and Characterisation
2.5. Expression of SpyCatcher mi3 and MBP SpyTag Proteins
2.6. Purification of SpyCatcher mi3 NPs
2.7. Purification of MBP SpyTag
2.8. SpyCatcher mi3: CAP255 gp140 SpyTag/MBP SpyTag Conjugation Reactions
2.9. Negative Stain Electron Microscopy (NS-EM) Data Collection
2.10. NS-EM Image Processing
2.11. Cryogenic Electron Microscopy (Cryo-EM) Data Collection
2.12. Cryo-EM Image Processing
2.13. Model Building, Interpretation and Visualisation
2.14. Rabbit Immunisations
2.15. Anti-Env Binding Titres
2.16. Pseudovirus-Based Neutralisation Assays
3. Results
3.1. Design, Expression and Characterisation of CAP255 gp140 SpyTag and gp150 Proteins
3.2. Preparation and Coupling of Env-Nanoparticles
3.3. NS-EM Structural Analysis
3.4. Cryo-EM Single Particle Analysis
3.5. Rabbit Immunogenicity
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ahmed, S.; Parthasarathy, D.; Newhall, R.; Picard, T.; Aback, M.; Ratnapriya, S.; Arndt, W.; Vega-Rodriguez, W.; Kirk, N.M.; Liang, Y.; et al. Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens. NPJ Vaccines 2023, 8, 181. [Google Scholar] [CrossRef] [PubMed]
- Schiller, J.; Chackerian, B. Why HIV virions have low numbers of envelope spikes: Implications for vaccine development. PLoS Pathog. 2014, 10, e1004254. [Google Scholar] [CrossRef] [PubMed]
- Stano, A.; Leaman, D.P.; Kim, A.S.; Zhang, L.; Autin, L.; Ingale, J.; Gift, S.K.; Truong, J.; Wyatt, R.T.; Olson, A.J.; et al. Dense Array of Spikes on HIV-1 Virion Particles. J. Virol. 2017, 91, 10–1128. [Google Scholar] [CrossRef]
- Haynes, B.F.; Wiehe, K.; Borrow, P.; Saunders, K.O.; Korber, B.; Wagh, K.; McMichael, A.J.; Kelsoe, G.; Hahn, B.H.; Alt, F.; et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023, 23, 142–158. [Google Scholar] [CrossRef]
- Ringel, O.; Vieillard, V.; Debre, P.; Eichler, J.; Buning, H.; Dietrich, U. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Viruses 2018, 10, 197. [Google Scholar] [CrossRef]
- Wei, X.; Decker, J.M.; Wang, S.; Hui, H.; Kappes, J.C.; Wu, X.; Salazar-Gonzalez, J.F.; Salazar, M.G.; Kilby, J.M.; Saag, M.S.; et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422, 307–312. [Google Scholar] [CrossRef]
- Gao, Y.; Wijewardhana, C.; Mann, J.F.S. Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1. Front. Immunol. 2018, 9, 345. [Google Scholar] [CrossRef] [PubMed]
- Vijayan, V.; Mohapatra, A.; Uthaman, S.; Park, I.-K. Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials. Pharmaceutics 2019, 11, 534. [Google Scholar] [CrossRef]
- Manolova, V.; Flace, A.; Bauer, M.; Schwarz, K.; Saudan, P.; Bachmann, M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008, 38, 1404–1413. [Google Scholar] [CrossRef]
- Bachmann, M.F.; Jennings, G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10, 787–796. [Google Scholar] [CrossRef]
- Zabel, F.; Kündig, T.M.; Bachmann, M.F. Virus-induced humoral immunity: On how B cell responses are initiated. Curr. Opin. Virol. 2013, 3, 357–362. [Google Scholar] [CrossRef] [PubMed]
- Mu, Z.; Wiehe, K.; Saunders, K.O.; Henderson, R.; Cain, D.W.; Parks, R.; Martik, D.; Mansouri, K.; Edwards, R.J.; Newman, A.; et al. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep. 2022, 38, 110514. [Google Scholar] [CrossRef] [PubMed]
- Bruun, T.U.; Andersson, A.-M.C.; Draper, S.J.; Howarth, M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano 2018, 12, 8855–8866. [Google Scholar] [CrossRef]
- Hsia, Y.; Bale, J.B.; Gonen, S.; Shi, D.; Sheffler, W.; Fong, K.K.; Nattermann, U.; Xu, C.; Huang, P.-S.; Ravichandran, R.; et al. Correction: Corrigendum: Design of a hyperstable 60-subunit protein icosahedron. Nature 2016, 540, 150. [Google Scholar] [CrossRef] [PubMed]
- He, L.; Kumar, S.; Allen, J.D.; Huang, D.; Lin, X.; Mann, C.J.; Saye-Francisco, K.L.; Copps, J.; Sarkar, A.; Blizard, G.S.; et al. HIV-1 vaccine design through minimizing envelope metastability. Sci. Adv. 2018, 4, eaau6769. [Google Scholar] [CrossRef] [PubMed]
- Rahikainen, R.; Rijal, P.; Tan, T.K.; Wu, H.-J.; Andersson, A.-M.C.; Barrett, J.R.; Bowden, T.A.; Draper, S.J.; Townsend, A.R.; Howarth, M. Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation. Angew. Chem. Int. Ed. 2021, 60, 321–330. [Google Scholar] [CrossRef]
- Cohen, A.A.; Gnanapragasam PN, P.; Lee, Y.E.; Hoffman, P.R.; Ou, S.; Kakutani, L.M.; Keeffe, J.R.; Wu, H.-J.; Howarth, M.; West, A.P.; et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 2021, 371, 735–741. [Google Scholar] [CrossRef]
- Guo, Y.; He, W.; Mou, H.; Zhang, L.; Chang, J.; Peng, S.; Ojha, A.; Tavora, R.; Parcells, M.S.; Luo, G.; et al. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines. mBio 2021, 12, e00930-21. [Google Scholar] [CrossRef]
- Halfmann, P.J.; Castro, A.; Loeffler, K.; Frey, S.J.; Chiba, S.; Kawaoka, Y.; Kane, R.S. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. Bioeng. Transl. Med. 2021, 6, e10253. [Google Scholar] [CrossRef] [PubMed]
- Kang, Y.-F.; Sun, C.; Zhuang, Z.; Yuan, R.-Y.; Zheng, Q.; Li, J.-P.; Zhou, P.-P.; Chen, X.-C.; Liu, Z.; Zhang, X.; et al. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. ACS Nano 2021, 15, 2738–2752. [Google Scholar] [CrossRef] [PubMed]
- Tan, T.K.; Rijal, P.; Rahikainen, R.; Keeble, A.H.; Schimanski, L.; Hussain, S.; Harvey, R.; Hayes, J.W.; Edwards, J.C.; McLean, R.K. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat. Commun. 2021, 12, 542. [Google Scholar] [CrossRef] [PubMed]
- Cohen, A.A.; Yang, Z.; Gnanapragasam PN, P.; Ou, S.; Dam, K.A.; Wang, H.; Bjorkman, P.J. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS ONE 2021, 16, e0247963. [Google Scholar] [CrossRef] [PubMed]
- Brinkkemper, M.; Sliepen, K. Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. Vaccines 2019, 7, 76. [Google Scholar] [CrossRef]
- Brouwer, P.J.; Antanasijevic, A.; Berndsen, Z.; Yasmeen, A.; Fiala, B.; Bijl, T.P.; Bontjer, I.; Bale, J.B.; Sheffler, W.; Allen, J.D. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat. Commun. 2019, 10, 4272. [Google Scholar] [CrossRef]
- Brouwer, P.J.M.; Antanasijevic, A.; de Gast, M.; Allen, J.D.; Bijl, T.P.L.; Yasmeen, A.; Ravichandran, R.; Burger, J.A.; Ozorowski, G.; Torres, J.L.; et al. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ Vaccines 2021, 6, 24. [Google Scholar] [CrossRef]
- Chapman, R.; Jongwe, T.I.; Douglass, N.; Chege, G.; Williamson, A.-L. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice. PLoS ONE 2017, 12, e0173352. [Google Scholar] [CrossRef]
- Gray, E.S.; Madiga, M.C.; Hermanus, T.; Moore, P.L.; Wibmer, C.K.; Tumba, N.L.; Werner, L.; Mlisana, K.; Sibeko, S.; Williamson, C.; et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011, 85, 4828–4840. [Google Scholar] [CrossRef]
- Moyo-Gwete, T.; Ayres, F.; Mzindle, N.B.; Makhado, Z.; Manamela, N.P.; Richardson, S.I.; Kitchin, D.; van Graan, S.; van Heerden, J.; Parbhoo, N.; et al. Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model. Sci. Rep. 2024, 14, 13311. [Google Scholar] [CrossRef]
- Kovacs, J.M.; Noeldeke, E.; Ha, H.J.; Peng, H.; Rits-Volloch, S.; Harrison, S.C.; Chen, B. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc. Natl. Acad. Sci. USA 2014, 111, 18542–18547. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.K.; de Val, N.; Bale, S.; Guenaga, J.; Tran, K.; Feng, Y.; Dubrovskaya, V.; Ward, A.B.; Wyatt, R.T. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 2015, 11, 539–550. [Google Scholar] [CrossRef]
- Sanders, R.W.; Vesanen, M.; Schuelke, N.; Master, A.; Schiffner, L.; Kalyanaraman, R.; Paluch, M.; Berkhout, B.; Maddon, P.J.; Olson, W.C.; et al. Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. J. Virol. 2002, 76, 8875–8889. [Google Scholar] [CrossRef] [PubMed]
- Chapman, R.; van Diepen, M.; Galant, S.; Kruse, E.; Margolin, E.; Ximba, P.; Hermanus, T.; Moore, P.; Douglass, N.; Williamson, A.L.; et al. Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles. Vaccines 2020, 8, 54. [Google Scholar] [CrossRef] [PubMed]
- Tanzer, F.L.; Shephard, E.G.; Palmer, K.E.; Burger, M.; Williamson, A.L.; Rybicki, E.P. The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine. Virol. J. 2011, 8, 51. [Google Scholar] [CrossRef]
- van Diepen, M.T.; Chapman, R.; Douglass, N.; Galant, S.; Moore, P.L.; Margolin, E.; Ximba, P.; Morris, L.; Rybicki, E.P.; Williamson, A.-L. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. J. Virol. 2019, 93, e02155-18. [Google Scholar] [CrossRef]
- Zakeri, B.; Fierer, J.O.; Celik, E.; Chittock, E.C.; Schwarz-Linek, U.; Moy, V.T.; Howarth, M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 2012, 109, E690–E697. [Google Scholar] [CrossRef]
- Scarff, C.A.; Fuller, M.J.G.; Thompson, R.F.; Iadanza, M.G. Variations on Negative Stain Electron Microscopy Methods: Tools for Tackling Challenging Systems. J. Vis. Exp. 2018, e57199. [Google Scholar]
- Punjani, A.; Rubinstein, J.L.; Fleet, D.J.; Brubaker, M.A. cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 2017, 14, 290–296. [Google Scholar] [CrossRef]
- Scheres, S.H.W. Chapter Six—Processing of Structurally Heterogeneous Cryo-EM Data in RELION. In Methods in Enzymology; Crowther, R.A., Ed.; Academic Press: Cambridge, MA, USA, 2016; Volume 579, pp. 125–157. [Google Scholar]
- Dubochet, J.; Adrian, M.; Chang, J.J.; Homo, J.C.; Lepault, J.; McDowall, A.W.; Schultz, P. Cryo-electron microscopy of vitrified specimens. Q. Rev. Biophys. 1988, 21, 129–228. [Google Scholar] [CrossRef]
- Zeng, G.L.; Wang, W. Does Noise Weighting Matter in CT Iterative Reconstruction? IEEE Trans. Radiat. Plasma Med. Sci. 2017, 1, 68–75. [Google Scholar] [CrossRef]
- Rohou, A.; Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 2015, 192, 216–221. [Google Scholar] [CrossRef] [PubMed]
- Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Fierer, J.O.; Rapoport, T.A.; Howarth, M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag. J. Mol. Biol. 2014, 426, 309–317. [Google Scholar] [CrossRef] [PubMed]
- Kong, L.; He, L.; de Val, N.; Vora, N.; Morris, C.D.; Azadnia, P.; Sok, D.; Zhou, B.; Burton, D.R.; Ward, A.B.; et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 2016, 7, 12040. [Google Scholar] [CrossRef] [PubMed]
- Abramson, J.; Adler, J.; Dunger, J.; Evans, R.; Green, T.; Pritzel, A.; Ronneberger, O.; Willmore, L.; Ballard, A.J.; Bambrick, J.; et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024, 630, 493–500. [Google Scholar] [CrossRef]
- Croll, T.I. ISOLDE: A physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 2018, 74 Pt 6, 519–530. [Google Scholar] [CrossRef]
- Meng, E.C.; Goddard, T.D.; Pettersen, E.F.; Couch, G.S.; Pearson, Z.J.; Morris, J.H.; Ferrin, T.E. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023, 32, e4792. [Google Scholar] [CrossRef]
- Montefiori, D.C. Neutralizing antibodies take a swipe at HIV in vivo. Nat. Med. 2005, 11, 593–594. [Google Scholar] [CrossRef]
- Ximba, P.; Chapman, R.; Meyers, A.; Margolin, E.; van Diepen, M.; Sander, A.; Woodward, J.; Moore, P.; Williamson, A.L.; Rybicki, E. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein. Nanotechnology 2022, 33, 485102. [Google Scholar] [CrossRef]
- Asbach, B.; Kliche, A.; Kostler, J.; Perdiguero, B.; Esteban, M.; Jacobs, B.L.; Montefiori, D.C.; LaBranche, C.C.; Yates, N.L.; Tomaras, G.D.; et al. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J. Virol. 2016, 90, 4133–4149. [Google Scholar] [CrossRef] [PubMed]
- Li, S.S.; Kochar, N.K.; Elizaga, M.; Hay, C.M.; Wilson, G.J.; Cohen, K.W.; De Rosa, S.C.; Xu, R.; Ota-Setlik, A.; Morris, D.; et al. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8(+) T-Cell Responses by Interleukin-12 Plasmid DNA. Clin. Vaccine Immunol. 2017, 24, e00263-17. [Google Scholar] [CrossRef] [PubMed]
- Fullerton, S.W.; Griffiths, J.S.; Merkel, A.B.; Cheriyan, M.; Wymer, N.J.; Hutchins, M.J.; Fierke, C.A.; Toone, E.J.; Naismith, J.H. Mechanism of the Class I KDPG aldolase. Bioorg Med. Chem. 2006, 14, 3002–3010. [Google Scholar] [CrossRef]
- McCarthy, S.; Gonen, S. Improved interface packing and design opportunities revealed by CryoEM analysis of a designed protein nanocage. Heliyon 2022, 8, e12280. [Google Scholar] [CrossRef]
- Patel, D.R.; Minns, A.M.; Sim, D.G.; Field, C.J.; Kerr, A.E.; Heinly, T.A.; Luley, E.H.; Rossi, R.M.; Bator, C.M.; Moustafa, I.M.; et al. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model. Microbiol. Spectr. 2024, 12, e0499822. [Google Scholar] [CrossRef]
- Shirasaki, T.; Feng, H.; Duyvesteyn HM, E.; Fusco, W.G.; McKnight, K.L.; Xie, L.; Boyce, M.; Kumar, S.; Barouch-Bentov, R.; Gonzalez-Lopez, O.; et al. Nonlytic cellular release of hepatitis A virus requires dual capsid recruitment of the ESCRT-associated Bro1 domain proteins HD-PTP and ALIX. PLoS Pathog. 2022, 18, e1010543. [Google Scholar] [CrossRef]
- Votteler, J.; Ogohara, C.; Yi, S.; Hsia, Y.; Nattermann, U.; Belnap, D.M.; King, N.P.; Sundquist, W.I. Designed proteins induce the formation of nanocage-containing extracellular vesicles. Nature 2016, 540, 292–295. [Google Scholar] [CrossRef] [PubMed]
- Antanasijevic, A.; Ueda, G.; Brouwer PJ, M.; Copps, J.; Huang, D.; Allen, J.D.; Cottrell, C.A.; Yasmeen, A.; Sewall, L.M.; Bontjer, I.; et al. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathog. 2020, 16, e1008665. [Google Scholar] [CrossRef]
- Sliepen, K.; Ozorowski, G.; Burger, J.A.; van Montfort, T.; Stunnenberg, M.; LaBranche, C.; Montefiori, D.C.; Moore, J.P.; Ward, A.B.; Sanders, R.W. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology 2015, 12, 82. [Google Scholar] [CrossRef]
- Wolfe, L.S.; Smedley, J.G., 3rd; Bubna, N.; Hussain, A.; Harper, R.; Mostafa, S. Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates. Vaccine 2021, 39, 3852–3861. [Google Scholar] [CrossRef]
- Gulla, K.; Cibelli, N.; Cooper, J.W.; Fuller, H.C.; Schneiderman, Z.; Witter, S.; Zhang, Y.; Changela, A.; Geng, H.; Hatcher, C.; et al. A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. Vaccine 2021, 39, 3379–3387. [Google Scholar] [CrossRef]
- Ozorowski, G.; Cupo, A.; Golabek, M.; LoPiccolo, M.; Ketas, T.A.; Cavallary, M.; Cottrell, C.A.; Klasse, P.J.; Ward, A.B.; Moore, J.P. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. J. Virol. 2018, 92, 10–1128. [Google Scholar] [CrossRef]
- Kraft, J.C.; Pham, M.N.; Shehata, L.; Brinkkemper, M.; Boyoglu-Barnum, S.; Sprouse, K.R.; Walls, A.C.; Cheng, S.; Murphy, M.; Pettie, D.; et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell Rep. Med. 2022, 3, 100780. [Google Scholar] [CrossRef]
- Sliepen, K.; Schermer, E.; Bontjer, I.; Burger, J.A.; Levai, R.F.; Mundsperger, P.; Brouwer PJ, M.; Tolazzi, M.; Farsang, A.; Katinger, D.; et al. Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ Vaccines 2021, 6, 103. [Google Scholar] [CrossRef]
- Asbach, B.; Kibler, K.V.; Kostler, J.; Perdiguero, B.; Yates, N.L.; Stanfield-Oakley, S.; Tomaras, G.D.; Kao, S.F.; Foulds, K.E.; Roederer, M.; et al. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J. Virol. 2019, 93, 10–1128. [Google Scholar] [CrossRef]
- Beavis, A.C.; Dienger-Stambaugh, K.; Briggs, K.; Chen, Z.; Abraham, M.; Spearman, P.; He, B. AJ Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice. Vaccine 2024, 42, 2347–2356. [Google Scholar] [CrossRef]
- Gomez, C.E.; Perdiguero, B.; Usero, L.; Marcos-Villar, L.; Miralles, L.; Leal, L.; Sorzano CO, S.; Sanchez-Corzo, C.; Plana, M.; Garcia, F.; et al. Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. Vaccines 2021, 9, 959. [Google Scholar] [CrossRef]
- Li, H.; Wang, S.; Hu, G.; Zhang, L.; Liu, S.; Lu, S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg. Microbes Infect. 2021, 10, 833–841. [Google Scholar] [CrossRef]
- Burton, S.; Spicer, L.M.; Charles, T.P.; Gangadhara, S.; Reddy, P.B.J.; Styles, T.M.; Velu, V.; Kasturi, S.P.; Legere, T.; Hunter, E.; et al. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability to Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. J. Virol. 2019, 93, 10–1128. [Google Scholar] [CrossRef]
Antibody | Neutralisation Breadth | Epitope | Native-Like Trimer | CAP255 | CAP256SU |
---|---|---|---|---|---|
PG9 | Broad | V2 apex | x | x | √ |
PGT128 | Broad | V3 glycan supersite | x | √ | √ |
VRC01 | Broad | CD4 binding site | x | √ | √ |
10E8 | Broad | MPER | x | √ | √ |
447-52D | Narrow * | V3 glycan | x | √ | √ |
PGT145 | Broad | V2 apex | √ | x | √ |
VRC26.08 | Broad | V2 apex | √ | x | √ |
F105 | Narrow | CD4 binding site | x | √ | √ |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Malebo, K.; Woodward, J.; Ximba, P.; Mkhize, Q.; Cingo, S.; Moyo-Gwete, T.; Moore, P.L.; Williamson, A.-L.; Chapman, R. Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies. Vaccines 2024, 12, 1063. https://doi.org/10.3390/vaccines12091063
Malebo K, Woodward J, Ximba P, Mkhize Q, Cingo S, Moyo-Gwete T, Moore PL, Williamson A-L, Chapman R. Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies. Vaccines. 2024; 12(9):1063. https://doi.org/10.3390/vaccines12091063
Chicago/Turabian StyleMalebo, Kegomoditswe, Jeremy Woodward, Phindile Ximba, Qiniso Mkhize, Sanele Cingo, Thandeka Moyo-Gwete, Penny L. Moore, Anna-Lise Williamson, and Rosamund Chapman. 2024. "Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies" Vaccines 12, no. 9: 1063. https://doi.org/10.3390/vaccines12091063